Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials
- PMID: 20050863
- DOI: 10.1111/j.1463-1318.2009.02184.x
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials
Abstract
Aim: The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer.
Method: Eligible studies were identified from Medline, Embase and the Cochrane Library. The end-points included overall survival and overall tumour response rate, and toxicity including leucopenia, febrile neutropenia, stomatitis/mucositis and diarrhoea.
Results: Five randomized controlled trials were identified. Pooled data demonstrated no difference in overall survival between the oral UFT plus LV regimen and the 5-FU bolus plus LV regimen [hazard ratio 1.013; 95% confidence interval (CI) 0.911-1.127].The fixed-effect pooled estimate for overall tumour response rate showed no significant difference between the two regimens (relative risk 0.893; 0.672-1.187). Grade 3-4 leucopenia [odds ratio (OR) 0.126; 955 CI 0.048-0.326], grade 1-4 leucopenia (OR 0.089; 95% CI 0.067-0.119) and grade1-4 febrile neutropenia (OR 0.020; 95% CI 0.004-0.102) were significantly less prominent in the oral UFT regimens. For nonhaematological toxicities, grade 3-4 stomatitis/mucositis (OR 0.075; 95% CI 0.039-0.146), grade 3-4 infection (OR 0.484; 95% CI 0.310-0.758), grade 1-4 infection (OR 0.672; 95% CI 0.547-0.826, P < 0.001), grade 1-4 diarrhoea (OR 0.743; 95% CI 0.626-0.881) were also less likely to happen in patients in the oral UFT plus LV regimen, while there was no significant difference between the two treatment regimens with respect to grade 1-4 stomatitis/mucositis (OR 0.278; 95% CI 0.053-1.456) and grade 3-4 (OR 1.174; 95% CI 0.983-1.403) diarrhoea.
Conclusion: Oral UFT or 5-FU bolus combined with LV results in similar overall survival and tumour response rates for advanced colorectal cancer. The former treatment regimen is greatly superior in terms of toxicity, especially haematological toxicity.
© 2011 The Authors. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland.
Similar articles
-
A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.Surg Oncol. 2010 Mar;19(1):38-45. doi: 10.1016/j.suronc.2009.02.015. Epub 2009 Apr 2. Surg Oncol. 2010. PMID: 19345093
-
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.J Clin Oncol. 2002 Sep 1;20(17):3605-16. doi: 10.1200/JCO.2002.04.123. J Clin Oncol. 2002. PMID: 12202661 Clinical Trial.
-
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.J Clin Oncol. 2004 Sep 1;22(17):3466-74. doi: 10.1200/JCO.2004.05.017. Epub 2004 Jul 26. J Clin Oncol. 2004. PMID: 15277535 Clinical Trial.
-
UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.Anticancer Drugs. 1998 Jul;9(6):479-90. Anticancer Drugs. 1998. PMID: 9877235 Review.
-
Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.Oncology (Williston Park). 1998 Oct;12(10 Suppl 7):28-34. Oncology (Williston Park). 1998. PMID: 9830622 Review.
Cited by
-
Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis.South Asian J Cancer. 2022 Feb 2;11(1):84-94. doi: 10.1055/s-0041-1735650. eCollection 2022 Jan. South Asian J Cancer. 2022. PMID: 35833043 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical